文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

增强癌症免疫疗法：利用铁死亡和免疫检查点阻断的药物递送系统

Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade.

作者信息

Zhang Ting, Gu Fanlin, Lin Wei, Shao Haiyan, Jiang Aiguo, Guan Xingang

机构信息

The First People's Hospital of Wenling (Taizhou University Affiliated Wenling Hospital), School of Medicine, Taizhou University, Taizhou, Zhejiang, China.

College of Medical Technology, Beihua University, Jilin, Jilin, China.

出版信息

Front Immunol. 2025 Jun 25;16:1611299. doi: 10.3389/fimmu.2025.1611299. eCollection 2025.

DOI:10.3389/fimmu.2025.1611299
PMID:40636119
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12238054/
Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, significantly improving outcomes for various malignancies. Despite their clinical success, only a subset of patients benefits from ICIs treatment, underscoring the need for innovative strategies to enhance their therapeutic potential. Ferroptosis, a unique form of programmed cell death driven by iron-dependent lipid peroxidation, has emerged as a promising partner for enhanced immunotherapy. Combining ferroptosis inducers with immune checkpoint blockade has shown promising potential in improving the efficacy of cancer immunotherapy. This study explores the mechanisms of ferroptosis and immune checkpoint inhibitors for synergistic cancer treatment, and reviews recent delivery platforms integrating ferroptosis and immune checkpoint blockade for enhanced therapy.

摘要

免疫检查点抑制剂（ICIs）彻底改变了癌症治疗方式，显著改善了各种恶性肿瘤的治疗效果。尽管它们在临床上取得了成功，但只有一部分患者能从ICIs治疗中获益，这凸显了需要创新策略来提高其治疗潜力。铁死亡是一种由铁依赖性脂质过氧化驱动的独特程序性细胞死亡形式，已成为增强免疫治疗的一个有前景的合作伙伴。将铁死亡诱导剂与免疫检查点阻断相结合在提高癌症免疫治疗疗效方面显示出有前景的潜力。本研究探讨了铁死亡和免疫检查点抑制剂协同治疗癌症的机制，并综述了最近整合铁死亡和免疫检查点阻断以增强治疗效果的递送平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/12238054/b58a6232cce5/fimmu-16-1611299-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/12238054/843ba4528e15/fimmu-16-1611299-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/12238054/b58a6232cce5/fimmu-16-1611299-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/12238054/843ba4528e15/fimmu-16-1611299-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/961e/12238054/b58a6232cce5/fimmu-16-1611299-g002.jpg

相似文献

[1]
Boosting cancer immunotherapy: drug delivery systems leveraging ferroptosis and immune checkpoint blockade.

Front Immunol. 2025-6-25

[2]
Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.

Clin Exp Med. 2025-7-8

[3]
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.

Immunotherapy. 2025-4

[4]
Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.

Front Immunol. 2024

[5]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[6]
Matrix stiffness-dependent PD-L2 deficiency improves SMYD3/xCT-mediated ferroptosis and the efficacy of anti-PD-1 in HCC.

J Adv Res. 2025-7

[7]
Combined programmed cell death protein 1 and cytotoxic T-lymphocyte associated protein 4 blockade in an international cohort of patients with acral lentiginous melanoma.

Br J Dermatol. 2025-1-24

[8]
Low dose radiotherapy combined with immune checkpoint inhibitors induces ferroptosis in lung cancer via the Nrf2/HO-1/GPX4 axis.

Front Immunol. 2025-5-27

[9]
Review Article: Probiotics-Mediated Enhancement of Checkpoint Inhibitor Blockade for HER2+ Breast Cancer.

Crit Rev Oncog. 2025

[10]
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.

Cochrane Database Syst Rev. 2024-8-13

引用本文的文献

[1]
Emerging dual role of ferroptosis in lung cancer (Review).

Oncol Rep. 2025-11

本文引用的文献

[1]
Engineered hybrid cell membrane nanovesicles for potentiated cancer immunotherapy through dual immune checkpoint inhibition.

Biomater Sci. 2025-5-13

[2]
Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer.

Mater Today Bio. 2025-2-21

[3]
RGD peptide-functionalized micelles loaded with crocetin ameliorate doxorubicin-induced cardiotoxicity.

Int J Pharm X. 2025-2-26

[4]
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8 T cells to promote antitumor immunity.

Cell. 2024-8-8

[5]
Ferroptotic therapy in cancer: benefits, side effects, and risks.

Mol Cancer. 2024-5-3

[6]
Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.

Biomed Pharmacother. 2024-5

[7]
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation.

Immunity. 2024-2-13

[8]
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.

Target Oncol. 2024-1

[9]
Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer.

Life Sci. 2024-2-15

[10]
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.

J Hematol Oncol. 2023-9-5

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索